• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance 0

Abbott Q1 Earnings & Revenues Top, ’18 View Retained

By Kurt Osterberg · On April 18, 2018

Abbott (ABT – Free Report) reported first-quarter 2018 adjusted earnings from continuing operations of 59 cents per share, beating the Zacks Consensus Estimate by a penny. The bottom line also improved 22.9% year over year and met the high end of the company’s guided range of 57-59 cents. Moreover, reported earnings in the quarter came in at 23 cents per share compared with the year-ago figure of 22 cents.

First-quarter worldwide sales came in at $7.39 billion, up 16.6% year over year on a reported basis. The top line also exceeded the Zacks Consensus Estimate of $7.26 billion by 1.8%.

On an organic basis, (adjusting for the impact of foreign exchange and certain divestments) sales increased 6.9% year over year in the reported quarter.

Quarter in Detail

Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition, and Diagnostics.

EPD sales rose 9.9% on a reported basis (up 6.8% on an organic basis) to $1.04 billion. This included a positive impact of 3.1% from currency fluctuations. Sales in the key emerging markets increased 8.7% (up 6.8%), driven by double-digit growth in India, China, and Brazil.

The Medical Devices business sales increased 14.6% on a reported basis to $2.74 billion. On an organic basis, sales grew 9.4%.

Cardiovascular and Neuromodulation sales reportedly (up 6.2% on an organic basis) rose 10.5% on double-digit growth in Electrophysiology and Neuromodulation.

Vascular product sales, however, declined 6% on a reported basis (up 1.6%). Within Rhythm Management, the company saw a sales increase of 4.7% on a reported basis (a decline of 1.2%).

Abbott Laboratories Price, Consensus and EPS Surprise

Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote

Diabetes Care sales improved 44.2% (up 32.9%), buoyed by double-digit international sales growth, led by a consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott.

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    5 Money-Making Action Tasks to Grow Your Business

  • Finance

    7 Powerful Ways to Trigger Imagination

  • Finance

    What You Need to Know About Angel Investors

No Comments

Leave a reply Cancel reply

Top Finance

  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce
  • Shark Tank Recap: Shed Defender, Tata Towels and Sanaia Applesauce Secure Deals Shark Tank Recap: Shed Defender, Tata Towels and Sanaia Applesauce Secure Deals
  • Hedge Funds In The US Hedge Funds In The US
  • One Ring To Rule Them All One Ring To Rule Them All
  • Dollar General (DG) Q2 Earnings And Revenues Surpass Estimates Dollar General (DG) Q2 Earnings And Revenues Surpass Estimates

New Posts

  • 5 Money-Making Action Tasks to Grow Your Business

    5 Money-Making Action Tasks to Grow Your Business

    January 18, 2021
  • 7 Powerful Ways to Trigger Imagination

    7 Powerful Ways to Trigger Imagination

    January 17, 2021
  • What You Need to Know About Angel Investors

    What You Need to Know About Angel Investors

    January 17, 2021
  • Build Your Agency’s Team of Advisors: Which Roles Do You Need?

    Build Your Agency’s Team of Advisors: Which Roles Do You Need?

    January 17, 2021
  • ‘Yes, And’ vs ‘Yes, But’ – When to Let Go of Your Buts

    ‘Yes, And’ vs ‘Yes, But’ – When to Let Go of Your Buts

    January 17, 2021
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018 NJCEE. All Rights Reserved.